SEC Seal
SEC Banner
Search the Next-Generation EDGAR System
Filing Detail
Form 10-Q - Quarterly report [Sections 13 or 15(d)]:
SEC Accession No. 0000950170-22-009714
Filing Date
2022-05-12
Accepted
2022-05-12 16:32:29
Documents
73
Period of Report
2022-03-31

Document Format Files

Seq Description Document Type Size
1 10-Q tals-20220331.htm   iXBRL 10-Q 2812714
2 EX-31.1 tals-ex31_1.htm EX-31.1 17706
3 EX-31.2 tals-ex31_2.htm EX-31.2 17731
4 EX-32.1 tals-ex32_1.htm EX-32.1 10490
5 EX-32.2 tals-ex32_2.htm EX-32.2 10780
  Complete submission text file 0000950170-22-009714.txt   9400418

Data Files

Seq Description Document Type Size
6 XBRL TAXONOMY EXTENSION LABEL LINKBASE DOCUMENT tals-20220331_lab.xml EX-101.LAB 454829
7 XBRL TAXONOMY EXTENSION DEFINITION LINKBASE DOCUMENT tals-20220331_def.xml EX-101.DEF 228586
8 XBRL TAXONOMY EXTENSION SCHEMA DOCUMENT tals-20220331.xsd EX-101.SCH 51158
9 XBRL TAXONOMY EXTENSION CALCULATION LINKBASE DOCUMENT tals-20220331_cal.xml EX-101.CAL 41562
10 XBRL TAXONOMY EXTENSION PRESENTATION LINKBASE DOCUMENT tals-20220331_pre.xml EX-101.PRE 349064
67 EXTRACTED XBRL INSTANCE DOCUMENT tals-20220331_htm.xml XML 1740387
Mailing Address 93 WORCESTER STREET WELLESLEY MA 02481
Business Address 570 PRESTON ST. SUITE 400 LOUISVILLE KY 40202 502-398-9250
Talaris Therapeutics, Inc. (Filer) CIK: 0001827506 (see all company filings)

IRS No.: 000000000 | State of Incorp.: DE | Fiscal Year End: 1231
Type: 10-Q | Act: 34 | File No.: 001-40384 | Film No.: 22918398
SIC: 2836 Biological Products, (No Diagnostic Substances)